Snow

Lipum advances to phase II with capital raise, moves production to...

On leap day, Lipum published the year-end report for 2023, where CEO Ola Sandborgh describes the progress as a "flying start to an exciting...
Swiss Nordic Bio

Chordate’s CEO presented at Swiss Nordic Bio

On March 7, Swiss Nordic Bio convened for its annual partnering and investor conference, facilitating connections between Nordic and Swiss life science companies, investors,...
Cereno’s new Chief Medical Officer and Head of R&D comments on progress with CS1

Cereno’s new CMO and Head of R&D comments on progress with...

Cereno Scientific’s cardiovascular disease drug candidate CS1 has shown potential for clinical benefit both in preclinical studies as well as in the ongoing phase...
Biosergen rights issue

Rights issue to give Biosergen first in-human efficacy data

Recently having closed a partnership deal with Alkem, Biosergen is advancing its antifungal drug candidate BSG005 through clinical studies. With Alkem later financing phase...
BioInvent’s CEO comments on the study success in China

BioInvent’s CEO comments on the study success in China

BioInvent’s partner in China, CASI Pharmaceuticals, has announced preliminary encouraging efficacy data for BioInvent’s lead drug candidate BI-1206 in combination with rituximab in cancer...
BioSergen CEO Tine Kold Olesen and CFO Niels Laursen in BioStock Studio

Biosergen attacks invisible threat of fungal infections

How big is the threat of fungal infections and the strains that develop drug resistance? Swedish biotech company Biosergen develops antimyotic drugs that they...
Elicera Material Transfers Agreement USA

Elicera collaborates with US cancer centre to evaluate iTANK

Elicera Therapeutics is the sole biotech in Sweden developing CAR T-cell therapies. Beyond that, the company has developed a technology - the iTANK platform...
Tine Kold Olesen, CEO Biosergen

Biosergen CEO: “Positive data give us a strong value proposition”

Biosergen is carrying out a SEK 40.5 million rights issue to conduct a first-in-patient safety and efficacy study with the antifungal drug candidate BSG005....
Neola starts usability study

Neola initiates usability study ahead of FDA approval

Lund-based Neola Medical continues to advance towards clinical studies with its lung monitoring system. The company is now starting a usability study - an...
Cyxones CEO Carl-Magnus Högerkorp

Cyxone’s CEO gives a status update

Cyxone recently reached a milestone in its rheumatoid arthritis project, rabeximod, when succeeding in identifying the molecule's target protein. This means that it is...